4/22
04:46 pm
sgmo
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) [Yahoo! Finance]
Low
Report
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) [Yahoo! Finance]
4/22
04:35 pm
sgmo
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Low
Report
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
3/25
03:09 pm
sgmo
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]
Medium
Report
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]
3/22
08:16 am
sgmo
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering [Yahoo! Finance]
High
Report
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering [Yahoo! Finance]
3/22
08:05 am
sgmo
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
High
Report
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
3/19
08:09 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.
3/18
03:11 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/18
03:06 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
3/13
08:54 am
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/13
08:12 am
sgmo
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs [Yahoo! Finance]
High
Report
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs [Yahoo! Finance]
3/13
08:05 am
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
High
Report
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
3/13
08:01 am
sgmo
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
High
Report
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
3/12
06:36 pm
sgmo
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast [Yahoo! Finance]
3/12
06:30 pm
sgmo
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Medium
Report
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
2/13
01:24 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/12
01:20 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
2/12
08:17 am
sgmo
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners [Yahoo! Finance]
High
Report
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners [Yahoo! Finance]
2/12
08:17 am
sgmo
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease [Yahoo! Finance]
High
Report
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease [Yahoo! Finance]
2/12
08:05 am
sgmo
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Low
Report
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
2/6
09:02 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
High
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
2/5
06:09 pm
sgmo
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile [Yahoo! Finance]
2/5
06:01 pm
sgmo
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
Medium
Report
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
2/2
01:05 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/1
07:13 pm
sgmo
Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. "Revolutionizing Regenerative Medicine: The Booming Frontier of Synthetic Stem Cells Unleashes Hope and Healing"– PMI Leads the Way [Yahoo! Finance]
Medium
Report
Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. "Revolutionizing Regenerative Medicine: The Booming Frontier of Synthetic Stem Cells Unleashes Hope and Healing"– PMI Leads the Way [Yahoo! Finance]
1/29
07:37 am
sgmo
Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's [Seeking Alpha]
Low
Report
Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's [Seeking Alpha]